US biotech giant Amgen (Nasdaq: AMGN) announced financial results for the third quarter of 2020 at close of market on Wednesday, showing that total revenues increased 12% to $6.42 billion, just ahead of analyst estimates of $6.38 billion, driven by higher volume growth, partially offset by lower net selling prices and the effects of the COVID-19 pandemic.
Amgen shares advanced 1.2% in after-hours trading, following a 3.2% decline in the regular session to close at $216.38.
Product sales increased 12% globally, driven by 18% volume growth across a number of Amgen’s newer products, including Otezla (apremilast), Mvasi (bevacizumab-awwb), Kanjinti (trastuzumab-anns), and Repatha (evolocumab), partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze